The Clinical Efficacy of Three Different Follicle-Stimulating Hormones for Follicle Growth and Development in Long-Protocol Controlled Ovarian Hyperstimulation Treatment
Xi-Qian Zhang,Li-Jia Zhang,Xiu-Lan Zhu,Hong Xu,Yan-Qun Luo,Li Yao,Qian-Wen Huang,Ying-Qi Nong,Wen-Juan Liu,Feng-Hua Liu
DOI: https://doi.org/10.2147/DDDT.S316189
2021-08-17
Abstract:Xi-Qian Zhang, &ast Li-Jia Zhang, &ast Xiu-Lan Zhu, Hong Xu, Yan-Qun Luo, Li Yao, Qian-Wen Huang, Ying-Qi Nong, Wen-Juan Liu, Feng-Hua Liu Reproductive Medical Center, Guangdong Women and Children Hospital, Guangzhou, 511442, People's Republic of China &astThese authors contributed equally to this work Correspondence: Feng-Hua Liu Department of Reproductive Medical Center, Guangdong Women and Children Hospital, No. 521 Xingnan Road, Panyu District, Guangzhou, 511442, Guangdong Province, People's Republic of China Tel +86 20-3915 1861 Fax +86 20-3915 1617 Email Objective: To compare the use and clinical efficacy of three different follicle-stimulating hormones (FSHs) for follicle growth and development in long-protocol controlled ovarian hyperstimulation (COH). Methods: A total of 540 gonadotropin-releasing hormone (GnRH) agonists' long protocol treatment cycles at our hospital between January 2015 and May 2020 and met the inclusion criteria were retrospectively analyzed. The cycles were divided into three groups based on their indexes (groups A, B, and C). Each of the groups received a different type of FSH during treatment. A cross-group comparison was then undertaken to evaluate the growth and development of the three largest follicles and the patients' pregnancy-related indexes between the normal-response and high-response populations. Results: In the normal-response populations, the number of high-quality embryos obtained in groups A and B was significantly higher than in group C, and the FSH dosage was significantly lower than in group C ( P < 0.05). There were more follicles with a diameter of 16– 18 mm found in group A than in group C on the day of hCG injection (hCG day) ( P < 0.05), but there were no significant differences in the groups in other indicators. In the high-response populations, the number of oocytes retrieved and high-quality embryos obtained in group A were significantly higher than in group C ( P < 0.05), and the total dosage and duration of FSH stimulation in group C were significantly higher than groups A and B ( P < 0.05). Conclusion: Three different types of FSH led to comparable growth rates of the three largest follicles and clinical pregnancy rates per fresh cycle in long-protocol COH treatment. Keywords: follicle-stimulating hormone, follicle growth rate, high-quality embryos, Gn stimulation duration, follicle distribution on hCG day With the rapid development of society, lifestyle changes, increased stress, and increased environmental pollution, infertility rates are increasing. Previous studies have found that the incidence of infertility in China has reached 12.5–15%. 1 , 2 Controlled ovarian hyperstimulation (COH) is widely used in assisted reproductive techniques (ART), such as in vitro fertilization and embryo transfer. 3 , 4 Human follicle-stimulating hormones (hFSHs) have become the primary therapeutic agent for COH in ART. 5 These hormones induce multiple follicular production and maturation within a controlled range, expecting to obtain high-quality oocytes to improve clinical pregnancy rates. Currently, the most commonly used recombinant human FSHs (rFSHs) in China include the imported rFSH Gonal-f (Merck Serono, Switzerland), the domestic rFSH Jinsaiheng (GenSci, China), and the urinary FSH (uFSH) Lishenbao (Lizhu Pharmaceuticals, China). In order to provide a theoretical basis for clinical use, the present study compared the efficacy and application of these three FSHs by retrospectively analyzing follicular growth and development—indicated by the results of vaginal ultrasound monitoring—during COH. Patients who received COH treatment at Guangdong Women and Children's Hospital between January 2015 and May 2020 were selected, with the first follow-up on the fifth day after receiving FSH, the second follow-up on day eight, and the third follow-up on day ten. The patients were organized into groups based on age, anti-Müllerian hormone (AMH) levels, antral follicle count (AFC), body mass index (BMI), and the FSH drug they were given. Those who had received Gonal-f became group A, those who had received Jinsaiheng became group B, and those who had received Lishenbao became group C. Then, based on their AMH levels, each group was further divided into a low-response population (AMH 4.5 μg/L). As the number of patients in the low-response population was insufficient, only the normal-response and high-response populations were compared. In tot -Abstract Truncated-